Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
LRP6 CRISPR/Cas9 KO Plasmid (h): sc-400844
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LRP6 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the LRP6 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LRP6 Antibody (C-10): sc-25317
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LRP6 CRISPR/Cas9 KO Plasmid (h) | sc-400844 | 20 µg | $397.00 |
Overview
LRP6 (low-density lipoprotein receptor-related protein 6) is a single-pass transmembrane co-receptor essential for canonical Wnt/β-catenin signaling, forming ligand-induced complexes with Frizzled receptors to promote Dishevelled recruitment and inhibition of the β-catenin destruction complex. Through this pathway, LRP6 regulates embryonic patterning, stem cell maintenance, cell proliferation, and differentiation, and it can integrate cues from extracellular antagonists such as DKK and sclerostin that modulate receptor availability. Altered LRP6 activity or expression has been associated with dysregulated Wnt signaling observed across diverse contexts including cancer biology, bone and metabolic phenotypes, and neurodevelopmental processes. As a membrane-proximal signaling node, LRP6 is frequently interrogated to dissect receptor trafficking, signalosome assembly, and pathway crosstalk affecting transcriptional programs downstream of β-catenin.
LRP6 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the LRP6 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the LRP6 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the LRP6 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish LRP6 protein expression.
This CRISPR knockout system enables efficient generation of LRP6-deficient cell models for investigation of LRP6 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting LRP6 exon(s) critical for LRP6 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple LRP6 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by LRP6 CRISPR/Cas9 KO Plasmid (h) and LRP6 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the LRP6 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by LRP6 HDR Plasmid (h) and LRP6 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by LRP6 homology arms to support homology-directed repair at defined LRP6 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.